Search
Vespula pensylvanica venom protein
go.drugbank.com/drugs/DB11031ApprovedVespula pensylvanica venom protein is an extract of Vespula pensylvanica venom. Vespula pensylvanica venom protein is used in allergenic testing.
Vespula vulgaris venom protein
go.drugbank.com/drugs/DB11033ApprovedVespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
Etomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalIt has been proposed as an induction anesthetic.
Chlorphenoxamine
go.drugbank.com/drugs/DB09007ApprovedWithdrawnIt is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Chlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
GTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Olaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It...
Bordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Alglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.